Current Issues of Pharmacy and Medical Sciences

A review of TTS – development, types and preparations

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 1, Pages 88-93


Chair and Department of Applied Pharmacy, Faculty of Pharmacy, Medical University of Lublin, Poland

DOI: 10.12923/j.2084-980X/26.1/a.19



Transdermal Therapeutic Systems (TTS) are elastic multi-layer patches applied to the skin in order to deliver active substances into the bloodstream. One advantage of a transdermal drug delivery route over other types of medication delivery is that the patch provides a noninvasive therapy, longer duration of drug activity, and improves most of bioavailability. TTS consist of a backing layer, a drug, an adhesive, and a release liner. TTS can be divided into five basic types of systems: reservoir, matrix, microreservoir, single-layer drug in adhesive, and multi-layer drug in adhesive. In order to improve the penetration of drugs through the skin, passive and active methods are used. The researchers are constantly developing new methods of improving the delivery of drugs applied by transdermal route. 


transdermal therapeutic system, transdermal drug delivery, permeation enhancers, active techniques, technology solutions


  1. Alexander A. et al.: Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J. Control. Release, 164(1), 26, 2012.
  2. Ammar H.O et al.: Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int. J. Pharm., 405(1/2), 142, 2011.
  3. Aquil M., Sultana Y. Ali A.: Matrix type transdermal drug delivery systems of metoprolol tartrate: In vitro characterization. Acta Pharm., 53 (2), 119, 2003.
  4. Bajaj S., Whiteman A., Brandner B.: Transdermal drug delivery in pain management. Contin. Educ. Anaesth. Crit. Care Pain, 11(2), 39, 2011. 
  5. Banga A.K., Bose S., Ghosh T.K.: Iontophoresis and electroporation: comparisons and contrasts. Int. J. Pharm., 179(1), 1, 1999.
  6. Barry B. (2002). Transdermal drug delivery. In: Pharmaceutics, The science of dosage forms design, ed. 2. Aulton E.M., Taylor K. (editors). London: Churchill Livingstone; 499.
  7. Bhunia T. et al.: A transdermal diltiazem hydrochloride delivery device using multi-walled carbon nanotube/poly(vinyl alcohol) composites. Carbon, 52, 305, 2013.
  8. Brown M.B. et al.: Transdermal drug delivery systems: skin perturbation devices. Methods Mol. Biol., 437, 119, 2008.
  9. Budhathoki U., Thapa P.: Effect of chemical enhancers on in vitro release salbutamol sulphate from transdermal patches. Kathmandu Univ. J. of Sci. Eng. Technol., 1(1), 1, 2005.
  10. Burkman R.T.: Transdermal hormonal contraception: benefits and risks. Am. J. Obstet. Gynecol., 197(2), 134.e1-6, 2007.
  11. Chen H. et al.: Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J. Control. Release, 139(1), 63, 2009.
  12. Davaran S. et al.: Development of a novel prolonged-release nicotine transdermal patch. Pharmacol. Res., 51(3), 233, 2005.
  13. Dittigen M. (2003). Transdermalne Systemy Terapeutyczne (TTS). In: Technologia nowoczesnych postaci leku. Muller R.H., Hildebrand G.E. (editors). Warszawa: PZWL, 121.
  14. Djabri A., Guy R.H., Delgado-Charro M.B.: Transdermal iontophoresis of ranitidine: an opportunity in paediatric drug therapy. Int. J. Pharm., 435(1), 27, 2012.
  15. El-Laithy H.M.: Novel transdermal delivery of timolol maleate using sugar esters: preclinical and clinical studies. Eur. J. Pharm. Biopharm., 72(1), 239, 2009.
  16. El-Laithy H.M. et al.: Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur. J. Pharm. Biopharm., 77(1), 43, 2011.
  17. El-Nabarawi M.A., et al.: Transdermal drug delivery of paroxetine through lipid-vesicular formulation to augment its bioavailability. Int. J. Pharm., 443(1/2), 307, 2013.
  18. Finnin B.C.: Transdermal drug delivery – What to expect in the near future. Business briefing: Pharmatech, 192, 2003.
  19. Gill H.S., Prausnitz M.R.: Coated microneedles for transdermal delivery. J. Control. Release, 117(2), 227, 2007.
  20. Giri A. et al.: Acrylic acid grafted guargum–nanosilica membranes for transdermal diclofenac delivery. Carbohydr. Polym., 91(2), 492, 2013.
  21. Gupta S.: Non-oral hormonal contraception. Curr. Obstet. Gynecol., 16(1), 30, 2006.
  22. Hadgraft, J., Guy, R.: Transdermal drug delivery. Marcel Dekker Inc., New York, 35, 296, 2003.
  23. Herwadkar A. et al.: Low frequency sonophoresis mediated transdermal and intradermal delivery of ketoprofen. Int. J. Pharm., 423(2), 289, 2012.
  24. Inui N. et al.: Novel patch for transdermal administration of morphine. J. Pain Symptom Manage., 44(4), 479, 2012.
  25. Janicki S., Fiebig A., Sznitowska M. (2008). Systemy terapeutyczne. In: Farmacja stosowana. Podręcznik dla studentów farmacji. Janicki S., Fiebig A., Sznitowska M. (editors). Warsaw: PZWL, 233.
  26. Jenerowicz D. et al.: Skin hypersensitivity reactions to transdermal therapeutic systems – still an important clinical problem. Ginekol. Pol., 83(1), 46, 2012.
  27. Kalia Y.N. et al.: Iontophoretic drug delivery. Adv. Drug Deliv. Rev., 56(5), 619, 2004.
  28. Khanna P. et al.: Skin penetration and fracture strength testing of silicon dioxide microneedles. Sens. Actuators A. Phys., 170(1/2), 180, 2011.
  29. Kim J.H. et al.: Simple fabrication of silver hybridized porous chitosan-based patch for transdermal drug-delivery system. Mater Lett., 95, 48, 2013.
  30. Kostrzewa-Itrych A., Itrych B.: The importance of medicine form in treating chronic and breakthrough pain based on morphine, fentanyl and buprenorphine preparations. Farm. Współcz., 4, 14, 2011.
  31. Li G. et al.: In vitro transdermal delivery of therapeutic antibodies using maltose microneedles. Int. J. Pharm., 368(1/2), 109, 2009.
  32. Li W.Z.: Super-short solid silicon microneedles for transdermal drug delivery applications. Int. J. Pharm., 389(1/2), 122, 2010.
  33. Martindale: The Complete Drug Reference. [online] London: Pharmaceutical Press <> (Accessed on 20.02.2013).
  34. Obata Y. et al.: A statistical approach to the development of a transdermal delivery system for ondansetron. Int. J. Pharm., 399(1/2), 87, 2010.
  35. Park C.W. et al.: Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system. Int. J. Pharm., 436(1/2), 32, 2012.
  36. Patel K.: Design of Diffusion Controlled Drug Delivery Systems, PhD thesis, Rensselaer Polytechnic Institute. New York, 2008.
  37. Pierce M.W.: Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics, 7(2), 159, 2010.
  38. Polat B.E., et al.: Ultrasound-mediated transdermal drug delivery: Mechanisms, scope, and emerging trends. J. Control. Release, 152(3), 330, 2011.
  39. Polish Pharmacopeia, IX Edition ,Vol. 1, Warsaw, 2011.
  40. Prausnitz M.R., Langer R.Ł.: Transdermal drug delivery. Nat. Biotechnol., 26(11), 1261, 2008.
  41. Raine T.R. et al.: Attitudes toward the vaginal ring and transdermal patch among adolescents and young women. J. Adolesc. Health., 45(3), 262, 2009.
  42. Ramesh G. et al.: Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. Cur. Drug Del., 4 (1), 69, 2007.
  43. Rios M.: Advances in transdermal technologies. Pharm. Technol., 31(10), 54, 2007.
  44. Sachdeva V. et al.: Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies. Int. J. Pharm., 41(1/2), 9, 2013.
  45. Sakamoto T. et al.: Non-destructive analysis of tulobuterol crystal reservoir-type transdermal tapes using near infrared spectroscopy and imaging. J. Pharm. Biomed. Anal., 74, 14, 2013.
  46. Sammeta S.M., Vaka S.R., Murthy S.N.: Transcutaneous electroporation mediated delivery of doxepin-HPCD complex: A sustained release approach for treatment of postherpetic neuralgia. J. Control. Release, 142(3), 361, 2010.
  47. Sammeta S.M., Vaka S.R., Murthy S.N.: Transcutaneous sampling of ciprofloxacin and 8-methoxypsoralen by electroporation (ETS technique). Int. J. Pharm., 369(1/2), 24, 2009.
  48. Singh S.: An overview of transdermal drug delivery. Drug Deliv. Report, Autumn/Winter, 35, 2005.
  49. Sitruk-Ware R., Nath A., Mishell D.R.Jr.: Contraception technology: past, present and future. Contraception, 87(3), 319, 2013.
  50. Tirnaksiz F., Yuce Z.: Development of transdermal system containing nicotine by using sustained release dosage design. Farmaco, 60(9), 763, 2005.
  51. Williams A.C., Barry B.W.: Penetration enhancers. Adv. Drug Deliv. Rev., 64(supp.), 128, 2012.
  52. Xavier A.C.F., de Moraes M.L., Ferreira M.: Immobilization of aloin encapsulated into liposomes in Layer-by-layer films for transdermal drug delivery. Mater. Sci. Eng.: C, 33(3), 1193, 2013.
  53. Zhao L. et al.: Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. Int. J. Pharm., 374(1/2), 73, 2009.
prev next



July 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31